Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Dipyridamole, an antiplatelet agent, synergizes with statins to induce cancer cell apoptosis.
• The precise mechanism of dipyridamole's potentiation of statin-induced apoptosis is not fully understood due to its polypharmacology.

Purpose of the Study:

• To identify the specific activity of dipyridamole responsible for its synergistic anticancer effect with statins.
• To investigate compounds that mimic dipyridamole's relevant activities and enhance statin-induced cell death.

Main Methods:

• Pharmacological screening of compounds to identify dipyridamole's cancer-related activities.
• Assessment of compounds' ability to potentiate statin-induced apoptosis in leukemia and myeloma cells.
• Evaluation of the role of cyclic adenosine monophosphate (cAMP) and sterol regulatory element-binding protein 2 (SREBP-2) in the observed potentiation.

Main Results:

• Phosphodiesterase (PDE) inhibitors, including cilostazol, that increase intracellular cyclic adenosine monophosphate (cAMP) levels potentiate statin-induced apoptosis in acute myeloid leukemia and multiple myeloma cells.
• Both dipyridamole and cilostazol inhibit statin-induced activation of sterol regulatory element-binding protein 2 (SREBP-2) in a cAMP-independent manner.
• A dual mechanism involving both cAMP-dependent and independent pathways contributes to the potentiation of statin-induced apoptosis.

Conclusions:

• PDE inhibitors like dipyridamole and cilostazol can synergize with statins to induce apoptosis in hematological malignancies through a dual mechanism.
• Clinically approved PDE inhibitors represent a readily available therapeutic strategy for combination with statins in treating blood cancers.
• Further clinical investigation of PDE inhibitors in combination with statins for hematological malignancies is warranted.